1 a case of fulminant varicella infection with purpura fulminans, hepatitis, and rhabdomyolysis

2 late-relapsing hepatitis after yellow fever

3 clinical and biochemical features of autoimmune hepatitis in 36 pediatric patients características clínicas e bioquímicas da hepatite autoimune em 36 pacientes pediátricos

4 pleural effusion- an unusual cause

5 reflexões éticas acerca dos estudos de soroprevelência de hepatites virais ethical issues about seroprevalence studies on viral hepatitis

6 carpal tunnel syndrome in hiv-positive patients coinfected with hcv

7 prospek tanaman obat sebagai antihepatitis

8 acute hepatitis in a child heterozygous for the i259v mefv gene variant

9 the spectrum of cutaneous infection in diabetic patients with hepatitis c virus infection: a single-center study from egypt

10 pruebas de laboratorio en el síndrome de gilbert consecutivo a hepatitis laboratory tests in gilbert's syndrome subsequent to hepatitis

11 a prospective study of hepatitis during antituberculous treatment in taiwanese patients and a review of the literature

12 micrornas in the evaluation and potential treatment of liver diseases

13 proposed electronic medical record with emphasis on hepatitis diagnosis

14 esteato-hepatite relacionada ao vírus da hepatite c: perfil clínico-histológico steatohepatitis related to hepatitis c virus: clinical and histological profiles

15 role of hepatic deposited immunoglobulin g in the pathogenesis of liver damage in systemic lupus erythematosus

16 exploitation of lipid components by viral and host proteins for hepatitis c virus infection

17 diagnóstico in vivo da asma brônquica

18 Quercetin treatment ameliorates inflammation and fibrosis in mice with nonalcoholic steatohepatitis.

19 Quercetin treatment ameliorates inflammation and fibrosis in mice with nonalcoholic steatohepatitis.

20 Synthesis and biological evaluation of (1,2,4)triazole[4,3-a]pyridine derivatives as potential therapeutic agents for concanavalin A-induced hepatitis.

21 Gold nanoparticles and hepatitis B virus

22 Prognostic profile of patients with non-viral hepatocellular carcinoma: A comparative study with hepatitis C virus-related hepatocellular carcinoma using data mining analysis.

23 Cost-effectiveness of direct anti-viral agents for hepatitis C virus infection and a combined intervention of syringe access and medication assisted therapy for opioid use disorders in an injection drug use population.

24 How expensive may drugs be? The example of hepatitis C drugs

25 The average effective dose of 4-amino-5-(furan-2-yl)-4H-1 ,2,4-triazole-3-thiol in experimental hepatitis

26 Prediction and Staging of Hepatic Fibrosis in Children with Hepatitis C Virus: A Machine Learning Approach.

27 Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C

28 Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience [Corrigendum]

29 Current progress in the prevention of mother-to-child transmission of hepatitis B and resulting clinical and programmatic implications

30 Comparison of pegylated interferon monotherapy and de novo pegylated interferon plus tenofovir combination therapy in patients with chronic hepatitis B

31 Reactivation of herpesvirus in patients with hepatitis C treated with direct-acting antiviral agents

32 Entecavir monotherapy versus de novo combination of lamivudine and adefovir for compensated hepatitis B virus-related cirrhosis: a real-world prospective multicenter cohort study

33 Prevalence and predictors of occult hepatitis C virus infection among Egyptian patients who achieved sustained virologic response to sofosbuvir/daclatasvir therapy: a multi-center study

34 Prevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus [Erratum]

35 Declining prevalence of hepatitis C virus among university students in one of the main governorates in Egypt

36 Baseline hepatitis C virus resistance-associated substitutions present at frequencies lower than 15% may be clinically significant

37 Poor adherence is a contributor to viral breakthrough in patients with chronic hepatitis B

38 Clinical and virological properties of hepatitis C virus genotype 4 infection in patients treated with different direct-acting antiviral agents

39 Entecavir add-on or switch-to pegylated interferon improves HBsAg clearance in HBe antigen negative chronic hepatitis B patients

40 Characterization of hepatitis C virus resistance to grazoprevir reveals complex patterns of mutations following on-treatment breakthrough that are not observed at relapse

41 Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience

42 Higher baseline viral diversity correlates with lower HBsAg decline following PEGylated interferon-alpha therapy in patients with HBeAg-positive chronic hepatitis B

43 Serum hepatitis B core antibody levels predict HBeAg seroconversion in chronic hepatitis B patients with high viral load treated with nucleos(t)ide analogs

44 Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection

45 Efficacy and safety of sofosbuvir–ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection

46 Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-naïve hepatitis C genotype 1b-infected patients in western China

47 Detection of hepatitis C virus (HCV) among health care providers in an Egyptian university hospital: different diagnostic modalities

48 Genotyping of HBV and tracking of resistance mutations in treatment-naïve patients with chronic hepatitis B

49 Conceptual framework for outcomes research studies of hepatitis C: an analytical review

50 Influence of host resistance on viral adaptation: hepatitis C virus as a case study

51 Approaches to hepatitis C treatment and cure using NS5A inhibitors

52 Safety and efficacy of entecavir for the treatment of chronic hepatitis B

53 Current treatment of choice for chronic hepatitis C infection

54 New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents

55 New approaches in the management of chronic hepatitis B: role of tenofovir

56 Hepatitis C virus-associated hepatocellular carcinoma as a second primary malignancy: exposing an overlooked presentation of liver cancer

57 Decreased hepatocellular carcinoma tumor burden with the achievement of hepatitis C virus sustained virologic response: unlocking the potential of T-cell-mediated immunosurveillance

58 Liver resection versus radiofrequency ablation for hepatitis B virus-related small hepatocellular carcinoma

59 Clinical significance of vascular endothelial growth factor in hepatitis C related hepatocellular carcinoma in Egyptian patients

60 Emerging role of dual antiplatelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma

61 Telaprevir-containing regimen for treatment of hepatitis C virus infection in patients with hepatocellular carcinoma awaiting liver transplantation: a case series

62 Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C

63 Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience [Corrigendum]

64 Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C

65 Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience [Corrigendum]

66 In Silico Screening of Aptamers Configuration against Hepatitis B Surface Antigen

67 Seroprevalence of Hepatitis B Virus and Associated Factors among Health Professionals in University of Gondar Hospital, Northwest Ethiopia

68 A Rare Case of Herpes Simplex Virus-2 Hepatitis with Negative Serology

69 Current progress in the prevention of mother-to-child transmission of hepatitis B and resulting clinical and programmatic implications

70 Comparison of pegylated interferon monotherapy and de novo pegylated interferon plus tenofovir combination therapy in patients with chronic hepatitis B

71 Reactivation of herpesvirus in patients with hepatitis C treated with direct-acting antiviral agents

72 Entecavir monotherapy versus de novo combination of lamivudine and adefovir for compensated hepatitis B virus-related cirrhosis: a real-world prospective multicenter cohort study

73 Prevalence and predictors of occult hepatitis C virus infection among Egyptian patients who achieved sustained virologic response to sofosbuvir/daclatasvir therapy: a multi-center study

74 Prevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus [Erratum]

75 Declining prevalence of hepatitis C virus among university students in one of the main governorates in Egypt

76 Baseline hepatitis C virus resistance-associated substitutions present at frequencies lower than 15% may be clinically significant

77 Poor adherence is a contributor to viral breakthrough in patients with chronic hepatitis B

78 Clinical and virological properties of hepatitis C virus genotype 4 infection in patients treated with different direct-acting antiviral agents

79 Entecavir add-on or switch-to pegylated interferon improves HBsAg clearance in HBe antigen negative chronic hepatitis B patients

80 Characterization of hepatitis C virus resistance to grazoprevir reveals complex patterns of mutations following on-treatment breakthrough that are not observed at relapse

81 Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience

82 Higher baseline viral diversity correlates with lower HBsAg decline following PEGylated interferon-alpha therapy in patients with HBeAg-positive chronic hepatitis B

83 Serum hepatitis B core antibody levels predict HBeAg seroconversion in chronic hepatitis B patients with high viral load treated with nucleos(t)ide analogs

84 Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection

85 Efficacy and safety of sofosbuvir–ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection

86 Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-naïve hepatitis C genotype 1b-infected patients in western China

87 Detection of hepatitis C virus (HCV) among health care providers in an Egyptian university hospital: different diagnostic modalities

88 Genotyping of HBV and tracking of resistance mutations in treatment-naïve patients with chronic hepatitis B

89 Conceptual framework for outcomes research studies of hepatitis C: an analytical review

90 Influence of host resistance on viral adaptation: hepatitis C virus as a case study

91 Approaches to hepatitis C treatment and cure using NS5A inhibitors

92 Safety and efficacy of entecavir for the treatment of chronic hepatitis B

93 Current treatment of choice for chronic hepatitis C infection

94 New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents

95 New approaches in the management of chronic hepatitis B: role of tenofovir

96 Hepatitis C virus-associated hepatocellular carcinoma as a second primary malignancy: exposing an overlooked presentation of liver cancer

97 Decreased hepatocellular carcinoma tumor burden with the achievement of hepatitis C virus sustained virologic response: unlocking the potential of T-cell-mediated immunosurveillance

98 Liver resection versus radiofrequency ablation for hepatitis B virus-related small hepatocellular carcinoma

99 Clinical significance of vascular endothelial growth factor in hepatitis C related hepatocellular carcinoma in Egyptian patients

100 Emerging role of dual antiplatelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma

101 Telaprevir-containing regimen for treatment of hepatitis C virus infection in patients with hepatocellular carcinoma awaiting liver transplantation: a case series

Keyword Connections

Journals

Research Groups

Bibliographies